Pfizer

  • 3 Basic Reasons Medical Marijuana Stocks Are Doomed For Failure

    By Nickey Friedman - August 31, 2013 | Tickers: BMY, MDBX, MJNA, MRK, MYL, PFE

    We've all seen it. Medical marijuana stocks are flying into the stratosphere as a new industry in America is born. What's not to get excited about? There are only a handful of public companies breaking into this new, multi-billion dollar industry with high hopes and expectations of giant windfalls in profits for all. As this article explains, nobody needs to sell the industry -- it sells itself! It sells more »

  • Can This HIV Drug Challenge Gilead’s Domination?

    By Kanak Kanti - August 19, 2013 | Tickers: GILD, GSK, PFE

    ViiV Healthcare, a joint venture by Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) formed in 2009 with both companies transferring their HIV assets to the new company, got FDA approval for its first new HIV product, Tivicay. Its original developer is Japan’s Shionogi Pharma, which the group joined last year.

    The drug has the potential of raising the groups’ fortunes to the tune of $5 billion provided it is more »

  • Is This New Lung Cancer Treatment a Game Changer?

    By Leo Sun - August 16, 2013 | Tickers: LLY, PFE, RHHBY

    Eli Lilly (NYSE: LLY) rallied on Aug. 13 after the pharmaceutical giant announced that its Phase III trial for a lung cancer treatment had succeeded in increasing the overall survival rate of patients. Analysts immediately speculated that this new treatment could become a blockbuster drug, possibly softening the blow from the upcoming patent expiration of Lilly’s best-selling product, Cymbalta.

    Is this unexpected victory reason to pick up shares of more »

  • A Sensible Acquisition by This Healthcare Company

    By usman iftikhar - August 15, 2013 | Tickers: ENDP, PFE, MDCO

    As competition gets stronger, companies attempt to consolidate operations. Although this consolidation is an expensive way to penetrate the market, in the pharmaceutical industry, this method brings safer growth. The smaller players especially are aiming to integrate with those who have their products in the second or third phases of clinical trials.

    That same strategy has been used by The Medicines Company (NASDAQ: MDCO). After passing the last stage of more »

  • Recession-Proof Your Portfolio

    By Ted Cooper - August 15, 2013 | Tickers: AAP, PFE, WM

    It is becoming clear that the Federal Reserve cannot continue to artificially prop up asset prices in a terrible economic environment. The data suggest that the U.S. could be headed for another recession in the coming quarters. Therefore, investors would be wise to recession-proof their portfolios.

    Some companies are better at weathering downturns than others because their products either are critical to the functioning of their customers or cater more »

  • The Next Big Opportunity in Antidepressant Drugs

    By Kanak Kanti - August 14, 2013 | Tickers: LLY, FRX, PFE

    The economic cost to the country of 16 million depressed Americans is $44 billion every year. Depression, concomitant with a sedentary lifestyle, is becoming a global phenomenon. It is the leading cause of disability among all medical illnesses. Technically known as Major Depressive Disorder (MDD), depression has a number of medications that are neither very effective nor very safe. Fetzima, a newly FDA-approved drug from Forest Laboratories (NYSE: FRX), promises more »

  • An All-In Bet on a Game-Changing Diabetes Treatment

    By Leo Sun - August 14, 2013 | Tickers: JNJ, MNKD, MRK, PFE

    Note: This article has been amended to correct the spelling of Afrezza. Motley Fool apologizes for the error.

    In the biotech industry, there are generally two kinds of companies -- those that have established top and bottom line growth from approved products, and those that have pipelines of experimental treatments with a high potential for growth. Conservative investors favor the former, which include well-known companies like Pfizer (NYSE: PFE), Merck (NYSE: MRKmore »)

  • TRGM: A Unique Story With Lots to “Bite Into”

    By Michal Vladimirsky - August 12, 2013 | Tickers: NSRGY, PFE

    Targeted Medical (TRGM) business model is not well understood, and the stock is trading at a severe discount to proper valuation based on sume of the parts, take-out multiple, and comps.  With 23m shares outstanding, but only ~5k traded daily, the stock is highly illiquid, and its market cap of $25m (coupled with this illiquidity) may not make this a suitable investment for many. Having said that, I believe that more »

  • Does a PayPal Spinoff Make Sense?

    By Timothy Green - August 12, 2013 | Tickers: EBAY, PFE, ZTS

    The ideal situation for a spinoff is when you have a small, fast growing division lodged within a large, slower-growing company. The new, fast-growing company commands a high P/E ratio while the large company is mostly unaffected by the loss of the division. This creates value for shareholders because the sum of the market values of the two companies is now greater than the original company.

    But sometimes, the more »

  • Why Catalyst Pharmaceutical Partners Is Rising On Heavy Trading

    By ned reding - August 11, 2013 | Tickers: ACAD, BMRN, CPRX, PFE

    On April 18th shares of Catalyst Pharmaceutical Partners (NASDAQ: CPRX) began spiking on heavy volume trading from $.47 to slightly over $1.00 in just three days. Since then, buying has remained heavy almost every day with the price recently hitting $1.61. Shares appear to be in a consolidation and are holding well over $1.20. Catalyst only has about 42 million shares outstanding, but since April 18 more »

  • A Closer Look at Pfizer’s Three-Way Split

    By Leo Sun - August 7, 2013 | Tickers: ABT, ACT, MRK, PFE, TEVA

    Last week, pharma giant Pfizer (NYSE: PFE) announced that it was planning to split the company into three businesses -- a move that had been long anticipated by analysts and investors alike. Although this move streamlines the company’s core businesses’ financials, does it change anything for investors?

    Prelude to a spin-off

    In its first business segment led by Geno Germano, Pfizer intends to group immunology and metabolic treatments together with more »

  • Can the Rise of the Global Old Help You Retire?

    By Paul Sangrey - August 6, 2013 | Tickers: MYL, NVS, PFE, TEVA

    Big Pharma is in trouble. U.S. pharmaceutical revenue fell for the first time on record last year because so many drugs came off of their patents, what was called as the patent cliff. In real terms, revenue fell by 3.5% according to the New York Times . Furthermore, another smaller but still notable patent cliff is coming in 2015.

    So, at first glance, now doesn't seem to be more »

  • A Closer Look at the Battle Over Cancer Treatments

    By Leo Sun - August 6, 2013 | Tickers: AMGN, INO, MRK, ONXX, PFE

    Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are struggling to avoid the upcoming patent cliff by acquiring companies with promising oncology treatments. In this article, I’ll take a look at several of the key companies to follow in this field, and what investors can expect from this fast more »

  • A Safe Investment With Growth Promise

    By Mohsin Saeed - August 6, 2013 | Tickers: AZN, PFE, TEVA

    Teva Pharmaceuticals (NYSE: TEVA) has been stuck is share purgatory for a number of years. There have been no capital gains, and the dividend yield is mediocre at best. This has forced Teva to undertake a radical overhaul of its business strategy.

    The recently-released second quarter results did not reflect the effects of this improved business strategy. Teva barely managed to meet expectations, with margins and revenues below expectations.

    However more »

  • Buy These Leading Pharma Companies

    By Shweta Dubey - August 6, 2013 | Tickers: BMY, JNJ, PFE

    A recent EvaluatePharma report estimated the market for prescribed drugs will increase at an annual rate of 3.8% to $895 billion from 2012 to 2018. New patents and improvement in research and development will bolster companies’ portfolios, while a growing population and better access to healthcare will be key factors driving the market size for drugs. Pharmaceutical companies are working hard to capitalize on the growing market. Three such more »

  • Respiratory Drug Maker About to Take Off

    By usman iftikhar - August 3, 2013 | Tickers: NVS, PFE, THRX

    Chronic obstructive pulmonary disease (COPD) is America’s third leading cause of death. It is a lung disease caused due to continuous poor airflow as a result of which the lung tissues breakdown. More than 80% of the cases are due to smoking and tend to worsen with increase in age and smoke intake.

    When over 13 million people in the US are affected by a single disease then it more »

  • These Pharmaceutical Giants Are Teetering Dangerously Near The Patent Cliff

    By Bob Ciura - August 2, 2013 | Tickers: BMY, LLY, PFE

    In the hunt for sustainable dividend yields, investors have rushed into the stocks of major pharmaceutical companies. These stocks are widely bought for their blue chip status and hefty dividend yields. Investors likely feel peace of mind buying these stocks, as medicine and health care are fairly recession-proof.

    At the same time, the industry is at an important inflection point. Several big pharma companies are struggling with patent cliffs, which more »

  • Who Stands to Lose the Most From This Biotech Breakup?

    By Leo Sun - August 2, 2013 | Tickers: BAX, HALO, PFE, RHHBY, VPHM

    Shares of ViroPharma (NASDAQ: VPHM) and Halozyme Therapeutics (NASDAQ: HALO) dropped in tandem on August 1, after ViroPharma discontinued a Phase II study of administering its flagship drug, Cinryze, subcutaneously with Halozyme’s recombinant human enzyme technology. ViroPharma shares declined nearly 7% after the announcement, but Halozyme plunged almost 14%, due to ViroPharma’s statement that it would pursue similar studies for subcutaneous injection by using other products, which raised more »

  • Out With the Old, In With the New in Treating MS

    By Ryan Guenette - July 31, 2013 | Tickers: BIIB, NVS, PFE, SNY, TEVA

    Hidden beneath all the numbers and metrics in Biogen Idec's (NASDAQ: BIIB) recent earnings report  is a key confirmation of a shifting market in the treatment of multiple sclerosis. This alteration could yield billions of dollars for companies positioned to take advantage of it. 

    What Happened

    On July 25, Biogen reported second-quarter financial results. Earnings of $2.30 per share and revenue of $1.7 billion both trumped estimates more »

  • Is This Company Getting Ahead of Itself?

    By Nicholas Kitonyi - July 30, 2013 | Tickers: LLY, JNJ, NVS, PFE

    The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are usually massive. In the most recent quarter, biotech company Eli Lilly (NYSE: LLY) reported earnings that beat analyst estimates and boosted guidance for the next quarter and the current fiscal year.

    The company is counting on various products in the pipeline, which could change its outlook more »

  • Page 1 of 25